Q-omics provides the consensus-scored UMOD profile across patient tissues and cancer cell-line models. UMOD expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, UMOD is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, UMOD RNA expression shows 8,628 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, KIRC, and PDAC as cancer lineages where UMOD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UMOD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UMOD survival associations across molecular data types. UMOD RNA expression shows survival associations in the most cancer types (15), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UMOD RNA expression–survival associations across cancer types. High UMOD expression shows unfavorable associations in ACC, COAD, LUSC, LGG, MESO and LIHC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for UMOD RNA expression.
This table summarizes UMOD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for UMOD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UMOD shows lower tumor expression in KIRC, KICH, KIRP, COAD and ESCA and higher tumor expression in BRCA. The KIRC box plot shows higher UMOD RNA expression in normal versus tumor tissue (log2 FC = −11.465, t-test p < 0.001).
This table shows molecular features associated with UMOD in patient tissues and cancer cell lines. In patient samples, UMOD shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, UMOD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
